AMS Earnings Prediction
The chart below shows how AMS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AMS sees a -7.75% change in stock price 10 days leading up to the earnings, and a +1.71% change 10 days following the report. On the earnings day itself, the stock moves by +2.36%. This data can give you a slight idea of what to expect for the next quarter's release.
AMS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
7.00M
36.33%
-0.81%
Gross Margin
19.57%
-52.20%
-44.05%
Operating Margin
-7.90%
-210.49%
-197.41%
Net Margin
-5.86%
-282.55%
-110.97%
EPS
-0.03
-250.00%
-105.45%
No Data Available
AMS Earnings Analysis
American Shared Hospital Services Corporation (AMS.A) Earnings Conference Call
Positive
Strong Revenue Growth: We reported another quarter of strong revenue growth totaling $6.99 million, up 36% year-over-year from $5.1 million in Q3 2023, driven by the Rhode Island acquisition and the new facility in Puebla, Mexico.
Patient Services Revenue Surge: Revenue from the Patient Services or Retail segment surged to $3.7 million, a remarkable increase of 273% compared to $988,000 in the same quarter last year, primarily due to the Rhode Island acquisition and Puebla operations.
Revenue Increase Overview: For the first nine months of 2024, revenue increased 23.3% to $19.27 million compared to $15.63 million for the same period in 2023, showcasing consistent growth across the business.
Bargain Purchase Gain: The bargain purchase gain from the Rhode Island acquisition increased by $263,000 net of income taxes in Q3, reflecting the successful valuation and recoverability of acquired assets.
Strong Cash Position: As of September 30, 2024, the company maintained a strong cash position with over $14.1 million in cash and equivalents, equating to approximately $2.17 per share, providing a solid foundation for future growth initiatives.
Negative
Gamma Knife Revenue Decline: Total Gamma Knife revenue decreased by 32.9% to $1.82 million due to the expiration of 1 contract in the third quarter of 2023 as well as 2 months of downtime at one of our sites due to a scheduled equipment upgrade and staffing shortage 2 of our other sites.
Operating Loss Analysis: The operating loss for the third quarter of 2024 was $889,000 compared to a slight operating income of $90,000, primarily due to increased operating costs from the company's recently acquired facilities in Rhode Island and the company's new facility in Puebla, Mexico, combined with lower Gamma Knife treatment volumes.
Gross Margin Decline: Gross margin for the third quarter of 2024 decreased to $1.37 million compared to gross margin of $2.10 million for the third quarter of 2023, which was affected by lower Gamma Knife treatment volumes and the strong growth from our patient services segment, which has a lower gross margin.
Increased Selling Costs: Selling and administrative costs increased to $1.93 million for the third quarter of 2024 compared to $1.74 million in the year ago quarter, due to acquisition and development costs for Rhode Island as well as legal fees.
Net Loss Comparison: Net loss attributable to American Shared Hospital Services in the third quarter of 2024 was $207,000 or $0.03 per diluted share, compared to net income of $118,000 or $0.02 per diluted share for the third quarter of 2023.
AMS FAQs
How does AMS typically perform around its earnings report dates?
Is American Shared Hospital Services (AMS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AMS Earning Call Sentiment
American Shared Hospital Services (AMS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AMS.A
-1.94%Positive
The earnings call highlights several concerns: declining gross margins, increased net losses, and operational challenges, notably staffing shortages and equipment issues. While revenue growth is positive, the lack of shareholder return plans and avoidance of stock buyback discussions contribute to negative sentiment. The Q&A reveals further costs and challenges, particularly with new acquisitions. The company's focus on long-term growth over immediate returns may not satisfy short-term investor expectations, leading to a likely stock price decline of -2% to -8% over the next two weeks.